FGF-1 for Topical Administration for the Treatment of Diabetic or Venous Stasis Ulcers

NCT00425178 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

8

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Wounds
Diabetes
Venous Stasis Ulcers

Interventions

DRUG: FGF-1

Sponsor

CardioVascular BioTherapeutics, Inc.

Collaborators

[object Object]